Compare Ginkgo Bioworks Holdings Inc (DNA) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Wix.Com Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.12 (market cap $590.53M), while Wix.Com Ltd trades at $53.28 (market cap $2.21B). The key difference: Wix.Com Ltd is far larger — about 3.7× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| DNA | WIX | |
|---|---|---|
Market Cap | $590.53M | $2.21B |
Sector | Health | Technology |
52-Week High | $16.14 | $184.24 |
52-Week Low | $5.48 | $40.43 |
Enterprise Value | $627.78M | $1.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Wix trades at $52.41, up 4.53% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue grew to $1.99B in 2025, though net income fell to $50.65M, and the stock carries a high P/E of 62.84. Recent news highlights AI-related volatility and a partnership with Elavon to enhance small business payments.
The outlook is mixed: strong analyst consensus (67.5% buy ratings) and a $83.13 price target suggest upside, but risks include legal investigations, expense spikes, and negative shareholder equity. Earnings misses in Q1 2026 and high valuation metrics warrant caution despite growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
